Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 548

Sort by

Sort Order Select

Journal Articles

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia

Bing Z. Carter, Po Yee Mak, Edward Ayoub, Xiaogang Wu, Baozhen Ke, Yuki Nishida, Andrew Futreal, Lauren B. Ostermann, Andrea D. Bedoy, Steffen Boettcher, Courtney D. DiNardo, Anna Puzio-Kuter, Masha V. Poyurovsky, Arnold Levine, Michael Andreeff

Blood (2025) 146 (21): 2574–2588.

https://doi.org/10.1182/blood.2025028935

Published: 2025

Includes: Supplemental data

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Blood blood.2024027948.

https://doi.org/10.1182/blood.2024027948

Published: 2025

Includes: Supplemental data

Journal Articles

MRD intervention in AML: A new therapeutic horizon

Andrew H Wei, Harry J Iland, Courtney D. DiNardo, John Reynolds

Blood blood.2025029010.

https://doi.org/10.1182/blood.2025029010

Published: 2025

Journal Articles

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Blood (2025) 146 (7): 874–886.

https://doi.org/10.1182/blood.2024027170

Published: 2025

Includes: Supplemental data

Journal Articles

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Blood (2025) 145 (25): 3015–3029.

https://doi.org/10.1182/blood.2024027244

Published: 2025

Includes: Supplemental data

Journal Articles

How I treat acute myeloid leukemia with differentiation therapy

Ghayas C. Issa, Eytan M. Stein, Courtney D. DiNardo

Blood (2025) 145 (12): 1251–1259.

https://doi.org/10.1182/blood.2024024008

Published: 2025

Journal Articles

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

Blood (2024) 144 (23): 2402–2416.

https://doi.org/10.1182/blood.2024025023

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

Blood (2024) 144 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2024-210642

Published: 2024

Journal Articles

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Blood (2024) 144 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2024-198928

Published: 2024

Journal Articles

Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Vanthana Bharathi, Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Elias Jabbour, Naval Daver, Nicholas J. Short, Koichi Takahashi, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, William G. Wierda, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4272.

https://doi.org/10.1182/blood-2024-209157

Published: 2024

Journal Articles

Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Jennifer Croden, Danielle Hammond, Kelly S. Chien, Abhishek Maiti, George Donovan Tippett, Guillermo Montalban-Bravo, Michael Morales, Nicholas J. Short, Hussein A. Abbas, Ghayas C. Issa, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2024-207476

Published: 2024

Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood (2024) 144 (Supplement 1): 735.

https://doi.org/10.1182/blood-2024-203706

Published: 2024

Journal Articles

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 734.

https://doi.org/10.1182/blood-2024-203459

Published: 2024

Journal Articles

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Eitan Kugler, Hagop M. Kantarjian, Alexandre Bazinet, Wei-Ying Jen, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Jayastu Senapati, Gautam Borthakur, Naveen Pemmaraju, Ghayas C. Issa, Alex Bataller, Patrick K. Reville, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2861.

https://doi.org/10.1182/blood-2024-199903

Published: 2024

Journal Articles

Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis

Eitan Kugler, Sanam Loghavi, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Ghayas C. Issa, Hussein A. Abbas, Prithviraj Bose, Jayastu Senapati, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 2857.

https://doi.org/10.1182/blood-2024-199917

Published: 2024

Journal Articles

Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2024-205504

Published: 2024

Journal Articles

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Blood (2024) 144 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2024-202429

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

MRD intervention in AML: A new therapeutic horizon

BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

How I treat acute myeloid leukemia with differentiation therapy

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis

Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only